| Application no. and date | 17729694.4 (espacenet) (Federated) (European Patent Register), 20170601 | | Patent/reg. no. and date | DK/EP 3464285, 20220921 | | Publication date | 20190410 | | Priority no. and date | US 201662344170 P, 20160601, US 201662418657 P, 20161107 | | EP pub. no. and date |
EP 3464285 20190410 | | Effective date | | | Applicant/owner | BioSplice Therapeutics, Inc., 9360 Towne Centre Drive
San Diego, CA 92121, US | | Applicant ref. no. | 1640077 | | Inventor | KC, Sunil Kumar, 10504 Clasico Court
San Diego
CA 92127, US | | Representative | RWS Group, RWS Compass House
Vanwall Business Park, Vanwall Road
Maidenhead, Berkshire
SL6 4UB, GB | | Opponent | | | IPC Class | C07D 471/04 (2006.01) | | Title | FREMGANGSMÅDE TIL FREMSTILLING AF N-(5-(3-(7-(3-FLUORPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMID | | Int. application no. | US2017035411 | | Int. publication no. | WO2017210407 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
